Focused Issues more

Vol 3, No 6 (December 2014): Personalized Therapy in Lung Cancer More >>
Vol 3, No 5 (October 2014): the 14th Central European Lung Cancer Conference (CELCC) More >>
Vol 3, No 3 (June 2014): The 4th European Lung Cancer Conference (ELCC) More >>

Original Article

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Review Article

Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond
Christine Khoo, Toni-Maree Rogers, Andrew Fellowes, Anthony Bell, Stephen Fox

Original Article

BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

Maintenance Therapy

Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?
Yoshihisa Kobayashi, Tetsuya Mitsudomi
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach
Javier de Castro Carpeño, Cristóbal Belda-Iniesta
Irreversible EGFR-TKIs: dreaming perfection
Lorenza Landi, Federico Cappuzzo
Angiogenesis in cancer: anti-VEGF escape mechanisms
Gerald W. Prager, Marina Poettler, Matthias Unseld, Christoph C. Zielinski
MET inhibition in lung cancer
Jessica Menis, Matteo Giaj Levra, Silvia Novello
Activated RET and ROS: two new driver mutations in lung adenocarcinoma
Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus, Reinhard Buettner, Juergen Wolf
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Potential toxicities of prophylactic cranial irradiation
Frank A. Giordano, Grit Welzel, Yasser Abo-Madyan, Frederik Wenz
ALK and ROS1 as a joint target for the treatment of lung cancer: a review
Raimon Puig de la Bellacasa, Niki Karachaliou, Roger Estrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
Ana Christina Garrido-Castro, Enriqueta Felip
From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
José Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, Rafael Rosell
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Are three doses of SABR (stereotactic ablative radiotherapy) more effective than 30 doses of conventional radiotherapy?
Anna O. Simeonova, Katharina Fleckenstein, Hans-Jörg Wertz, Judit Boda-Heggemann, Frederik Wenz
Cetuximab in non-small-cell lung cancer
Robert Pirker, Martin Filipits
FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications
Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf, Reinhard Buettner
MET inhibitors in combination with other therapies in non-small cell lung cancer
Sukhmani Padda, Joel W. Neal, Heather A. Wakelee
Adaptive resistance to targeted therapies in cancer
Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, Amaya Gasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao, Alejandro Martínez Bueno
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Rathi N. Pillai, Suresh S. Ramalingam

China Lung Cancer Research Highlight

The use of quantitative proteomics towards biomarker discovery in lung squamous cell carcinoma
Timothy G. Whitsett, Landon J. Inge, Nhan L. Tran

Editorials

New insights into the functional consequences of ephrin A3 mutations in non-small cell lung cancer
Timothy G. Whitsett, Joseph C. Loftus, Jeffrey A. Winkles, Nhan L. Tran